Capital market firm Echelon Wealth Partners, Inc. has begun research into pharmaceutical Company
Kalytera Therapeutics Inc. (
TSX: V.KALY,
OTCQB: KALTF,
Forum) and on Tuesday gave it a speculative “buy” rating with a one-year price target of $0.30 per share.
More information can be found
here.
KALY, a pioneer in cannabidiol (CBD) therapeutics,
also made news this weekwhen it issued 9,387,831 common shares of the Company to The Salzman Group, providers of clinical study management services in relation to the Company's Phase 2 study evaluating the use of CBD in the prevention of graft versus host disease.
FULL DISCLOSURE: Kalytera Therapeutics Inc. is a client of Stockhouse Publishing.